Clinical Trial: Efficacy and Safety of Stapokibart for Primary Cutaneous Amyloidosis

U.S., Aug. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07143864) titled 'Efficacy and Safety of Stapokibart for Primary Cutaneous Amyloidosis' on Aug. 13.

Brief Summary: This trial is planned to investigate the efficacy and safety of Stapokibart (an IL-4 receptor antagonist) in patients with PCA.

Study Start Date: Sept. 15

Study Type: INTERVENTIONAL

Condition: Primary Cutaneous Amyloidosis

Intervention: BIOLOGICAL: Stapokibart

A humanized monoclonal antibody that targets the interleukin (IL)-4 receptor subunit alpha

OTHER: Placebo drug

Placebo drugs without Stapokibart

Recruitment Status: NOT_YET_RECRUITING

Sponsor: First Affiliated Hospital of Chongqing Medical University

Information provide...